Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,419 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Solid Tumor Neoplasms Clear all
Completed No phase listed Observational

Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients

NCT02464098
View directory record Official record
Conditions
Diarrhea
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

NCT01164163
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 4, 2026, 5:52 AM EDT
Terminated Phase 1 Interventional

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00701298
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
peginterferon alfa-2b, decitabine, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 23, 2014 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT06131398
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
AMG 355, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

NCT02509598
View directory record Official record
Conditions
Rhabdomyosarcoma, Melanoma
Interventions
Tc99m tilmanocept, Vital Blue Dye (optional), Lymph Node Mapping
Drug · Procedure
Lead sponsor
Cardinal Health 414, LLC
Industry
Eligibility
Up to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Orlando, Florida • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 4, 2026, 5:52 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Community-Based Physical Activity Intervention for Underserved Cancer Survivors

NCT06206863
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Exercise Intervention, Questionnaire Administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

NCT00834704
View directory record Official record
Conditions
Solid Tumor
Interventions
PEGPH20
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Santa Monica, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

NCT00039052
View directory record Official record
Conditions
Breast Cancer, Kidney Cancer, Lung Cancer
Interventions
interleukin-4 PE38KDEL cytotoxin
Biological
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers

NCT00003249
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, chemotherapy, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 4, 2026, 5:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

NCT07594626
View directory record Official record
Conditions
Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Pemetrexed, PRMT5 Inhibitor BMS-986504
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Cabozantinib in Advanced Solid Malignancies

NCT01588821
View directory record Official record
Conditions
Lung Cancer, Solid Tumor (Not Breast or Prostate Cancers)
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

NCT02875548
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors

NCT00660426
View directory record Official record
Conditions
Advanced Gastrointestinal Malignancies, Solid Tumors
Interventions
Oxaliplatin, Gemcitabine, Capecitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 4, 2026, 5:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

NCT06425926
View directory record Official record
Conditions
Melanoma Stage IV, Solid Tumor
Interventions
GIM-531, Anti-PD-1 monoclonal antibody
Drug
Lead sponsor
Georgiamune Inc
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • Bakersfield, California • Fullerton, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

XK469 in Treating Patients With Advanced Solid Tumors

NCT00028548
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
R(+)XK469
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
16 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional Results available

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

NCT04537715
View directory record Official record
Conditions
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
Interventions
Tazemetostat, Itraconazole, Rifampin
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 4, 2026, 5:52 AM EDT
Active, not recruiting Phase 1 Interventional

A Monotherapy in Subjects With Advanced Solid Tumors

NCT04221204
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Highly selective FGFR1-3 inhibitor
Drug
Lead sponsor
3D Medicines (Beijing) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

NCT01340833
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

NCT00514215
View directory record Official record
Conditions
Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery
Biological · Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

NCT02004106
View directory record Official record
Conditions
Neoplasms
Interventions
RO6895882
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

NCT05668585
View directory record Official record
Conditions
Solid Tumors, Melanoma, NSCLC, CRC, ATC
Interventions
CFT1946, Trametinib, Cetuximab
Drug
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Sarasota, Florida • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 4, 2026, 5:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

NCT06721689
View directory record Official record
Conditions
Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Rhabdomyosarcoma, Refractory Rhabdomyosarcoma
Interventions
PEEL-224, Vincristine, Temozolomide (TMZ)
Drug
Lead sponsor
Theodore Laetsch
Other
Eligibility
1 Year to 30 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 4, 2026, 5:52 AM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 4, 2026, 5:52 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

NCT05255484
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
LM-108, An Anti-PD-1 Antibody
Drug
Lead sponsor
LaNova Medicines Limited
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Ocala, Florida • Indianapolis, Indiana • Canton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 4, 2026, 5:52 AM EDT